Evidence map›Paper›PMID 27771018›Full record

ArticleJournal of neuroimmunology2017

Bedside to bench to bedside research: Estrogen receptor beta ligand as a candidate neuroprotective treatment for multiple sclerosis.

Noriko Itoh, Roy Kim, Mavis Peng, Emma DiFilippo, Hadley Johnsonbaugh, Allan MacKenzie-Graham, Rhonda R Voskuhl

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroimmunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01466114 (A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis), which is not on this map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01466114 phase2unknown statusnot on this map

A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.

TypeinterventionalSponsorUniversity of California, Los AngelesRan2011 to 2022Enrolled64ConditionsRelapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple SclerosisArmsestriol, Placebo, Norethindrone, Progestin Placebo
3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Inhibition of neuroinflammation and neuronal damage by the selective non-steroidal ERβ agonist AC-186.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024
    Article
  6. Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol.Laboratory investigation; a journal of technical methods and pathology · 2023
    Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Cell-specific and region-specific transcriptomics in the multiple sclerosis model: Focus on astrocytes.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Noriko ItohDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA.
Roy KimDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA.
Mavis PengDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA.
Emma DiFilippoDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA.
Hadley JohnsonbaughDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA.
Allan MacKenzie-GrahamDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA.
Rhonda R VoskuhlDepartment of Neurology, University of California, Los Angeles, David Geffen School of Medicine, USA. Electronic address: rvoskuhl@ucla.edu.
University of California, Los Angeles · US

Funding

A Combination Trial of Copaxone Plus Estriol in RRMSR01NS051591 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2007 to 2013
$3.9M
Neuroendocrinology, Sex Differences, and ReproductionT32HD007228 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARNOLD, ARTHUR P · 1985 to 2015
$3.9M
Parental imprinting of the X chromosome: effects on neurodegenerationR01NS096748 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI VOSKUHL, RHONDA R · 2016 to 2020
$1.9M
NICHD NIH HHS T32 HD007228NINDS NIH HHS R01 NS051591NINDS NIH HHS R01 NS096748
6 · The paper itself

Abstract

Protective effects of pregnancy during MS have led to clinical trials of estriol, the pregnancy estrogen, in MS. Since estriol binds to estrogen receptor (ER) beta, ER beta ligand could represent a "next generation estriol" treatment. Here, ER beta ligand treatment was protective in EAE in both sexes and across genetic backgrounds. Neuroprotection was shown in spinal cord, sparing myelin and axons, and in brain, sparing neurons and synapses. Longitudinal in vivo MRIs showed decreased brain atrophy in cerebral cortex gray matter and cerebellum during EAE. Investigation of ER beta ligand as a neuroprotective treatment for MS is warranted.

Indexed as

AnimalsCyclohexanesEstrogen Receptor betaFemaleLigandsMaleMiceMice, Inbred C57BLMice, Inbred NODMultiple SclerosisNeuroprotective AgentsPhenolsTreatment OutcomeAC-186CyclohexanesEstrogen Receptor betaLigandsNeuroprotective AgentsPhenolsEstrogenExperimental autoimmune encephalomyelitisMultiple sclerosisNeuroprotectionPregnancy

Identifiers

PMID27771018
PMCPMC5806698
OpenAlexW2528674264

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.